Comparing the diagnostic potential of 68Ga-Alfatide II and 18F-FDG in differentiating between non small cell lung cancer and tuberculosis

Journal of Nuclear Medicine

Volumn 57, Issue 5, 2016, Pages 672-677

  Kang, Fei ^a   Wang, Shengjun ^a   Tian, Feng ^b   Zhao, Mingxuan ^a   Zhang, Mingru ^a   Wang, Zhe ^a   Li, Guoquan ^a   Liu, Changli ^c   Yang, Weidong ^a   Li, Xiaofei ^b   Wang, Jing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Tuberculosis Hospital of Shaanxi Province   (China)

Author keywords

18F FDG; 68Ga Alfatide II; Non small cell lung cancer; Tuberculosis

Indexed keywords

ALFATIDE II GA 68; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ALFATIDE II; CYCLOPEPTIDE; GALLIUM;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG DISTRIBUTION; DRUG UPTAKE; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG TUBERCULOSIS; MALE; NON SMALL CELL LUNG CANCER; PET-CT SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL LUNG CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; TUBERCULOSIS;

ADULT; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PEPTIDES, CYCLIC; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; TUBERCULOSIS;

EID: 84967057612     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.167924     Document Type: Article

References (36)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
2. Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015;13:515-524.
3. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 1998;16:1075-1084.
4. Hashimoto Y, Tsujikawa T, Kondo C, et al. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med. 2006;47:426-431.
5. Shetty N, Noronha V, Joshi A, et al. Diagnostic and treatment dilemma of dual pathology of lung cancer and disseminated tuberculosis. J Clin Oncol. 2014;32: E7-e9.
6. D'souza MM, Mondal A, Sharma R, Jaimini A, Khanna U. Tuberculosis the great mimicker: 18F-fludeoxyglucose positron emission tomography/computed tomography in a case of atypical spinal tuberculosis. Indian J Nucl Med. 2014;29: 99-101.
7. Prapruttam D, Hedgire SS, Mani SE, Chandramohan A, Shyamkumar NK, Harisinghani M. Tuberculosis: The great mimicker. Semin Ultrasound CT MR. 2014;35:195-214.
8. Li Y, Su M, Li F, Kuang A, Tian R. The value of 18F-FDG-PET/CT in the differential diagnosis of solitary pulmonary nodules in areas with a high incidence of tuberculosis. Ann Nucl Med. 2011;25:804-811.
9. Sathekge MM, Maes A, Pottel H, Stoltz A, Van deWiele C. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J. 2010;100:598-601.
10. Chen CJ, Lee BF, Yao WJ, et al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR. 2008;191:475-479.
11. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: Prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011-1019.
12. Haroon A, Zumla A, Bomanji J. Role of fluorine 18 fluorodeoxyglucose positron emission tomography-computed tomography in focal and generalized infectious and inflammatory disorders. Clin Infect Dis. 2012;54:1333-1341.
13. Kim IJ, Lee JS, KimSJ, et al. Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging. 2008;35:808-814.
14. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407: 249-257.
15. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated avb3 integrin in cancer patients by positron emission tomography and [18F] galacto-RGD. PLoS Med. 2005;2:e70.
16. Datta M, Via LE, Kamoun WS, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci USA. 2015;112:1827-1832.
17. Guo J, Lang L, Hu S, et al. Comparison of three dimeric 18F-AlF-NOTA-RGD tracers. Mol Imaging Biol. 2014;16:274-283.
18. Guo J, Guo N, Lang L, et al. 18F-alfatide II and 18F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy. J Nucl Med. 2014;55:154-160.
19. Zhu Z, Yin Y, Zheng K, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET/CT: A prospective proof-ofconcept cohort study. Ann Rheum Dis. 2014;73:1269-1272.
20. Sun Y, Zeng Y, Zhu Y, et al. Application of 68Ga-PRGD2 PET/CT for avb3-integrin imaging of myocardial infarction and stroke. Theranostics. 2014;4:778-786.
21. Peng J, Ouyang Y, Fang WD, et al. Differentiation of intracranial tuberculomas and high grade gliomas using proton MR spectroscopy and diffusion MR imaging. Eur J Radiol. 2012;81:4057-4063.
22. Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: A multicenter study. J Nucl Med. 2012;53:716-722.
23. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
24. Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879-886.
25. Bach-Gansmo T, Danielsson R, Saracco A, et al. Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med. 2006;47:1434-1439.
26. Kim JH, Lee JS, Kang KW, et al. Whole-body distribution and radiation dosimetry of 68Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging. Cancer Biother Radiopharm. 2012;27:65-71.
27. Zheng K, Liang N, Zhang J, et al. 68Ga-NOTA-PRGD2 PET/CT for integrin imaging in patients with lung cancer. J Nucl Med. 2015;12:1823-1827.
28. Mittra ES, Goris ML, Iagaru AH, et al. Pilot pharmacokinetic and dosimetric studies of 18F-FPPRGD2: A PET radiopharmaceutical agent for imaging avb3 integrin levels. Radiology. 2011;260:182-191.
29. Gao S, Wu H, Li W, et al. A pilot study imaging integrin avb3 with RGD PET/CT in suspected lung cancer patients. Eur J Nucl Med Mol Imaging. 2015; 42:2029-2037.
30. Yu C, Pan D, Mi B, et al. F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases. Eur J Nucl Med Mol Imaging. 2015;13:2021-2028.
31. Mi B, Yu C, Pan D, et al. Pilot Prospective evaluation of 18F-alfatide II for detection of skeletal metastases. Theranostics. 2015;5:1115-1121.
32. Beer AJ, Grosu AL, Carlsen J, et al. [18F]galacto-RGD positron emission tomography for imaging of avb3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13: 6610-6616.
33. Beer AJ, Niemeyer M, Carlsen J, et al. Patterns of avb3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET. J Nucl Med. 2008;49:255-259.
34. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ, Study G. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol. 2010;51:40-46.
35. Cobelens F, Van Kampen S, Ochodo E, Atun R, Lienhardt C. Research on implementation of interventions in tuberculosis control in low-and middleincome countries: A systematic review. PLoS Med. 2012;9:e1001358.
36. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-176.